In Reply We thank Merschhemke et al and Andrade for their interest in our article.1 We appreciate Merschhemke et al highlighting that data have been collected on patients participating in fingolimod trials for up to 3 months after drug cessation. However, these data have not, to our knowledge, been subjected to the peer-review process and published and, as such, were not available for our review when writing up our cases.
Hatcher SE, Waubant E, Graves JS. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation—Reply. JAMA Neurol. 2016;73(11):1376. doi:10.1001/jamaneurol.2016.3202
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: